Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 18/20 | 0.60 |
| ▸ | CHRM3 | P20309 | 11/20 | 0.60 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4142367 | 0.94 | ADRB2 (0.68) | ADRB2CHRM3ADRB3 | |
| SCHEMBL4164154 | 0.94 | ADRB2 (0.67) | ADRB2CHRM3ADRB3 | |
| SCHEMBL4160129 | 0.94 | ADRB2 (0.66) | ADRB2CHRM3ADRB1ADRB3 | |
| SCHEMBL4345217 | 0.93 | ADRB2 (0.65) | ADRB2CHRM3ADRB1ADRB3 | |
| SCHEMBL4144944 | 0.92 | ADRB2 (0.48) | ADRB2CHRM3ADRB1ADRB3CHRM2 | |
| SCHEMBL4157732 | 0.90 | ADRB2 (0.61) | ADRB2CHRM3ADRB1ADRB3 | |
| SCHEMBL4149628 | 0.90 | ADRB2 (0.67) | ADRB2CHRM3ADRB1ADRB3CHRM2 | |
| SCHEMBL4149624 | 0.90 | ADRB2 (0.67) | ADRB2CHRM3ADRB1ADRB3CHRM2 | |
| SCHEMBL4145088 | 0.88 | ADRB2 (0.64) | ADRB2CHRM3ADRB1CHRM2CHRM4 | |
| SCHEMBL4155144 | 0.88 | ADRB2 (0.64) | ADRB2CHRM3ADRB1CHRM2CHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-7612084-B2 | Amine derivatives for the treatment of asthma and COPD | PFIZER INC (US) | 2009-11-03 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20090253739-A1 | Amine Derivatives | PFIZER INC | 2009-10-08 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
| US-20070265303-A1 | Amine derivatives | PFIZER LIMITED | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265303-A1 | Amine derivatives | HNMT, HRH4, CMA1 | ADRB2 93/4885CHRM3 169/4885ADRB1 71/4885 |
| US-20090253739-A1 | Amine Derivatives | HNMT, HRH4, CMA1 | ADRB2 93/4885CHRM3 169/4885ADRB1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.